Abstract:Aim: Tacrolimus, an immunosuppressant used to prevent organ rejection in renal transplant patients, exhibits high inter-patient variability, necessitating therapeutic drug monitoring. Early post-transplant tacrolimus exposure in Hispanics is understudied. Although genotypic information is linked to pharmacokinetic differences, its clinical application remains limited. This study aimed to use a real-world data-driven, pharmacokinetic model-based approach for tacrolimus in Hispanics to determine a suitable initial dose and design an optimal dose titration strategy by simulations to achieve plasma trough concentration target levels of 10-12 ng/mL at the earliest. Methods: Sparse concentration-time data of tacrolimus were obtained from electronic medical records for self-identified Hispanic subjects following renal transplant. Rich pharmacokinetic literature data was leveraged to estimate structural pharmacokinetic model parameters, which were then fixed in the current analysis. Only apparent clearance was estimated with the sparse tacrolimus data and potential covariates were identified. Simulations of various starting doses and different dose titration strategies were then evaluated. Results: The analysis included 121 renal transplant patients with 2,215 trough tacrolimus concentrations. A two-compartment transit absorption model with allometrically scaled body weight and time-varying hematocrit on apparent clearance adequately described the data. The estimated apparent clearance was 13.7 L/h for a typical patient weighing 70 kg and at 30% hematocrit, demonstrating a 40% decrease in clearance compared to other patient populations. Model based simulations indicated the best initial dose for the Hispanic population is 0.1 mg/kg/day. The proposed titration strategy, with three dose adjustments based on trough levels of tacrolimus, increased the proportion of patients within the target range (10-12 ng/mL) more than 2.5-fold and decreased the proportion of patients outside the therapeutic window by 50% after the first week of treatment. Conclusion: Hispanic renal transplant population showed an estimated 40% decrease of apparent clearance in the typical patient compared to other populations with similar characteristics. The proposed dose adjustment attained the target range rapidly and safely. This study advocates for tailored tacrolimus dosing regimens based on population pharmacokinetics to optimize therapy in Hispanic renal transplant recipients.

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients

The Pharmacokinetic Study of Tacrolimus and Wuzhi Capsule in Chinese Liver Transplant Patients

Population Pharmacokinetics and Pharmacogenomics of Tacrolimus in Chinese Children Receiving a Liver Transplant: Initial Dose Recommendation

Initial Dosage Optimization of Tacrolimus in Chinese Pediatric Patients Undergoing Kidney Transplantation Based on Population Pharmacokinetics and Pharmacogenetics

[Population Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Patients].

Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation

A Population Pharmacokinetic Study of Tacrolimus in Healthy Chinese Volunteers and Liver Transplant Patients

Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients.

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients

Population Pharmacokinetics and Dosage Optimisation of Tacrolimus Coadministration with Wuzhi Capsule in Adult Liver Transplant Patients

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Population Pharmacokinetic Modeling Combined With Machine Learning Approach Improved Tacrolimus Trough Concentration Prediction in Chinese Adult Liver Transplant Recipients

Population Pharmacokinetics of Tacrolimus and CYP3A5, MDR1 and IL-10 Polymorphisms in Adult Liver Transplant Patients

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule

Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients

A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients

Weight, CYP3A5 Genotype, and Voriconazole Co-administration Influence Tacrolimus Initial Dosage in Pediatric Lung Transplantation Recipients with Low Hematocrit based on a Simulation Model

Optimizing tacrolimus dosing in Hispanic renal transplant patients: insights from real-world data